Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Surgeon General
  • Cigna’s ACA Exit
  • Visa Program
  • Medicaid Work Requirements
  • Gavin Newsom

TRENDING TOPICS:

  • Surgeon General
  • Cigna's ACA Exit
  • Visa Program
  • Medicaid Work Requirements
  • Gavin Newsom

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Thursday, Aug 30 2018

Full Issue

Even As Senate Is Poised To Pass Opioid Package, Many Controversial Issues Involving The Crisis Left Untouched

More contentious policies -- like protecting patient privacy and Medicaid funding -- are likely to be kicked down the road until the lame-duck session following the midterm elections. Meanwhile, the FDA wants to encourage the drug industry to develop nonaddictive alternatives to opioids, and the company that makes Narcan eyes schools as an untapped market.

Stat: The Senate Will Soon Vote On An Opioids Package, But A New Law Is Still Far Off 

The Senate is likely to pass a comprehensive bill to address the opioid crisis in the coming weeks. The House did so in June. But the finish line on that long-discussed priority remains a long way off. Lawmakers have left untouched many of the bill’s most contentious issues, like debates over patient privacy and expensive changes to Medicaid payments for addiction treatment. There’s no sign yet they’ll iron out those issues before the Senate votes. (Facher, 8/30)

The Washington Post: FDA Pushes For Development Of Non-Opioid Pain Medications

The Food and Drug Administration is planning new steps to encourage the development of nonaddictive alternatives to opioid pain medications, Commissioner Scott Gottlieb said in an interview. As part of the effort, the agency plans to withdraw its existing 2014 guidance to the drug industry on pain medicines. That document is overly broad, Gottlieb said, and is sometimes a barrier to new products and innovations. The current guidelines call for a large number of studies to get FDA approval for general use for chronic pain, he added. (McGinley, 8/29)

Bloomberg: Narcan Owner Sees Schools As Growth Area For Overdose Spray 

Emergent BioSolutions Inc. Chief Executive Officer Daniel J. Abdun-Nabi said he sees an untapped market in U.S. high schools and colleges for Narcan, the opioid-overdose nasal spray his company will market after its acquisition of Adapt Pharma Inc. Narcan is available in 1,144 high schools across 31 states and 309 colleges and universities in 35 states, Abdun-Nabi said Wednesday in an interview. That’s a small percentage of the nation’s more than 24,000 public high schools and over 4,000 colleges and universities, according to the National Center for Education Statistics. (Hopkins, 8/29)

And in the states —

Richmond Times-Dispatch: Virginia Moves Toward E-Prescribing Mandate For Opioids By 2020

A legislatively mandated work group of medical industry stakeholders agreed Wednesday on a set of recommended changes to the 2017 state law requiring the transition to e-prescribing of all opioids by July 2020. The law — part of an effort to lessen the abuse of the drugs — is intended to reduce errors, theft and forgery of prescriptions, and to help prescribers track what medications a patient has received as the state grapples with a public health crisis. (Balch, 8/29)

Cincinnati Enquirer: Can Medical Marijuana Fight Ohio's Opioid Epidemic?

[Leanne] Barbee and other advocates of Ohio’s coming medical-marijuana program say they hope to enlist the drug not just to help individuals avoid opioids for pain treatment but to break the addiction epidemic’s hold on the Buckeye State. (Saker and Schultz, 8/29)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Friday, May 1
  • Thursday, April 30
  • Wednesday, April 29
  • Tuesday, April 28
  • Monday, April 27
  • Friday, April 24
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF